A Look At IQVIA Holdings (IQV) Valuation After Charles River Deal And Fresh Analyst Coverage

robot
摘要生成中

IQVIA Holdings (IQV) is gaining investor attention following a planned acquisition of Charles River Laboratories’ discovery services assets and new analyst coverage. Despite recent positive share price movements, longer-term returns have been weaker. The company is currently considered 31.4% undervalued, with a narrative fair value of $250.00, driven by a record R&D Solutions backlog and strong demand for outsourced clinical research, particularly in specialized therapeutic areas.

此頁面可能包含第三方內容,僅供參考(非陳述或保證),不應被視為 Gate 認可其觀點表述,也不得被視為財務或專業建議。詳見聲明
  • 讚賞
  • 留言
  • 轉發
  • 分享
留言
請輸入留言內容
請輸入留言內容
暫無留言